Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice - Sorbonne Université
Journal Articles Molecular Therapy - Methods and Clinical Development Year : 2020

Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice

Abstract

Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disease caused by an absence of the dystrophin protein, which is essential for muscle fiber integrity. Among the developed therapeutic strategies for DMD, the exon-skipping approach corrects the frameshift and partially restores dystrophin expression. It could be achieved through the use of antisense sequences, such as peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) or the small nuclear RNA-U7 carried by an adeno-associated virus (AAV) vector. AAV-based gene therapy approaches have potential for use in DMD treatment but are subject to a major limitation: loss of the AAV genome, necessitating readministration of the vector, which is not currently possible, due to the immunogenicity of the capsid. The PPMO approach requires repeated administrations and results in only weak cardiac dystrophin expression. Here, we evaluated a combination of PPMO- and AAV-based therapy in a mouse model of severe DMD. Striking benefits of this combined therapy were observed in striated muscles, with marked improvements in heart and diaphragm structure and function, with unrivalled extent of survival, opening novel therapeutic perspectives for patients.
Fichier principal
Vignette du fichier
PIIS2329050120300413.pdf (4.47 Mo) Télécharger le fichier
Origin Publication funded by an institution
Loading...

Dates and versions

hal-02569939 , version 1 (11-05-2020)

Identifiers

Cite

Anne Forand, Antoine Muchir, Nathalie Mougenot, Caroline Sévoz-Couche, Cécile Peccate, et al.. Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice. Molecular Therapy - Methods and Clinical Development, 2020, 17, pp.695-708. ⟨10.1016/j.omtm.2020.03.011⟩. ⟨hal-02569939⟩
133 View
89 Download

Altmetric

Share

More